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Results of Transfemoral or Transapical
Aortic Valve Implantation Following a Uniform
Assessment in High-Risk Patients With Aortic Stenosis
Dominique Himbert, MD,* Fleur Descoutures, MD,* Nawwar Al-Attar, MD, PHD,†
Bernard Iung, MD,* Gregory Ducrocq, MD,* Delphine Détaint, MD,* Eric Brochet, MD,*
David Messika-Zeitoun, MD,* Fady Francis, MD,‡ Hassan Ibrahim, MD,§ Patrick Nataf, MD,†
Alec Vahanian, MD*
Paris, France
Objectives We sought to describe the results of a strategy offering either transfemoral or transapical aortic valve implanta-
tion in high-risk patients with severe aortic stenosis.
Background Results of transfemoral and transapical approaches have been reported separately, but rarely following a uni-
form assessment to select the procedure.
Methods Of 160 consecutive patients at high risk or with contraindications to surgery, referred between October 2006
and November 2008, 75 were treated with transcatheter aortic valve implantation. The transfemoral approach
was used as the first option and the transapical approach was chosen when contraindications to the former
were present. The valve used was the Edwards Lifesciences SAPIEN prosthesis.
Results Patients were age 82  8 years (mean  SD), in New York Heart Association functional classes III/IV, with predicted
mean surgical mortalities of 26  13% using the European System for Cardiac Operative Risk Evaluation and 16 
7% using the Society of Thoracic Surgeons Predicted Risk of Mortality. Fifty-one patients were treated via the trans-
femoral approach, and 24 via the transapical approach. The valve was implanted in 93% of the patients. Hospital
mortality was 10%. Mean ( SD) 1-year survivals were 78  6% in the whole cohort, 81  7% in the transfemoral
group, 74  9% in the transapical group (p  0.22), and 60  10% in the first 25 patients versus 93  4% in the
last 50 patients treated (p  0.001). In multivariate analysis, early experience was the only significant predictor
of late mortality.
Conclusions Being able to offer either transfemoral or transapical aortic valve implantation, within a uniform assessment,
expands the scope of the treatment of aortic stenosis in high-risk patients and provides satisfactory results at
1 year in this population. The results are strongly influenced by experience. (J Am Coll Cardiol 2009;54:
303–11) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.032r
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aortic stenosis (AS) is the most frequent valvular heart
isease in Western countries (1). Surgical aortic valve
eplacement (AVR) is the reference treatment. The possi-
ilities of treatment have expanded with the development of
ranscatheter aortic valve implantation (TAVI) techniques
2–16). Feasibility and favorable short-term outcomes of
AVI have been demonstrated, but mid- and long-term
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dwards Lifesciences and Sanofi-Aventis. Drs. Brochet and Nataf are proctoring
hysicians for Edwards Co. Dr. Vahanian is a consultant for Edwards Lifesciences.f
Manuscript received January 11, 2009; revised manuscript received March 30,
009, accepted April 1, 2009.esults need to be further evaluated (17). In addition, the
ransfemoral and transapical approaches have been studied
eparately, but very rarely as part of a strategy taking
dvantage of the availability of both techniques (18).
The aim of this study was to describe immediate and
-year results of TAVI following a uniform assessment
eading to the use of the transfemoral approach as the first
ption, or of the transapical approach in case of contrain-
ications to the transfemoral approach.
ethods
atients. From October 2006 to November 2008, among
ll patients with severe symptomatic AS consecutively re-
erred for TAVI by primary or tertiary hospitals or by
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Transcatheter Aortic Valve Implantation July 21, 2009:303–11independent cardiologists, those
who actually had a high surgical
risk or contraindications to AVR
were evaluated for TAVI.
Screening included clinical eval-
uation, transthoracic echocardiog-
raphy (TTE) and, if necessary,
transesophageal echocardiography
(TEE), coronary angiography,
aortic and femoroiliac angiogra-
phy, and multislice computed to-
mography. After multidisciplinary
evaluation including cardiologists,
cardiovascular surgeons, anesthesi-
ologists, and geriatricians, using
imaging and medicosurgical con-
ferences, the decision to perform
TAVI was made in patients with
severe symptomatic AS; contrain-
dications to, or high risk for AVR
European System for Cardiac Operative Risk Evaluation
EuroSCORE] 20% or Society of Thoracic Surgeons Pre-
icted Risk of Mortality [STS-PROM] 10%); life expect-
ncy 1 year (17,19–20); anatomy suitable for intervention
17,21); and no need for coronary bypass surgery.
These patients represent the study population. The trans-
emoral approach was considered as the first option, and the
ransapical approach was used when there were contraindi-
ations to the transfemoral route, which were mainly un-
uitable femoroiliac accesses and severely calcified aortic
rch and descending aorta (17). In patients with contrain-
ications to both approaches, AVR was reconsidered if the
perative risk was not considered prohibitive. In patients
ho were too frail to undergo any invasive intervention or
ith comorbidities that clearly limited short-term life ex-
ectancy or precluded future quality of life (mainly malig-
ancies and cognitive disorders), a medical treatment was
ecided upon. The formal decision algorithm is shown in
igure 1. The device used was the Edwards-SAPIEN valve
Edwards Lifesciences Inc., Irvine, California).
ransfemoral TAVI. Procedures were performed under
eneral anesthesia, with fluoroscopic and TEE guidance.
fter retrograde crossing and pre-dilation of the native
alve, the prosthesis was pushed by a flexible catheter
RetroFlex, Edwards Lifesciences) positioned within the
ortic valve, and then delivered by balloon inflation under
apid ventricular pacing. Technical aspects of the procedure
ave been detailed previously (3–7,15,17).
ransapical TAVI. After anterolateral mini-thoracotomy
nd pericardiotomy, the left ventricular apex was punctured
hrough purse-string sutures. Then, a sheath was introduced
n the left ventricle and the prosthesis was implanted using
he antegrade route via the Ascendra (Edwards Life-
ciences) system (11–14).
ollow-up. Hospital clinical and echocardiographic data
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
NYHA  New York Heart
Association
STS-PROM  Society of
Thoracic Surgeons
Predicted Risk of Mortality
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiographyere obtained before discharge. All adverse events were 2rospectively recorded. After the hospital phase, clinical and
TE follow-up was obtained in all survivors at 1 to 3
onths, 6 months, 1 year, and then annually.
utcomes. Outcomes were described according to the
uidelines for reporting mortality and morbidity after car-
iac valve interventions (22). Implantation success was
efined by valve implantation in the correct position. Major
ascular complications were defined as lesions requiring
mmediate or delayed vascular operations other than a
imple arterial suture, or leading to hospital death.
tatistical analysis. Data were expressed as mean  SD,
xcept for the length of stay, which was expressed as median
ith 25th to 75th percentiles. To assess experience, a binary
ariable was used to separate the first 25 patients from the
ast 50 patients. The Mann-Whitney U test was used to
ompare continuous variables in the transfemoral and
ransapical groups, and categorical variables were compared
y the chi-square or Fisher exact test. Survival rates between
roups were compared using the log-rank test. Analysis of
he predictive factors of late survival was performed using a
ultivariate Cox model including early versus late experi-
nce, transfemoral or transapical approach, and patient risk
core (EuroSCORE or STS-PROM score). All tests were
TF TAVI
n=51(32%)
TA TAVI
n=24(15%)
AVR
n=23(14%)
Medical Rx
n=62(39%)
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Figure 1 Management of High-Risk
Patients With Aortic Stenosis
Algorithm for treatment in 160 high-risk patients referred for transcatheter aor-
tic valve implantation (AVR). (a) Frailty (n  5); life expectancy too short (n 
20); quality of life too poor (n  20). (b) Annulus diameter too large (n  12);
bicuspid aortic valve (n  5); intracardiac thrombus (n  4). (c) Inadequate
iliac arteries (n  41); porcelain aorta (n  6); abdominal aortic aneurysm with
thrombus (n  4). (d) Severe respiratory failure (n  10); subaortic left ventric-
ular hypertrophy (n  3); miscellaneous (n  6). Several contraindications may
have been encountered in 1 patient. AVR  aortic valve replacement; CI  contra-
indication; EuroSCORE  European System for Cardiac Operative Risk Evaluation;
STS  Society of Thoracic Surgeons; TA  transapical; TAVI  transcatheter aortic
valve implantation; TF  transfemoral.-sided. A p value 0.05 was considered to indicate a
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July 21, 2009:303–11 Transcatheter Aortic Valve Implantationtatistically significant difference. Statistical analysis was
erformed using statistical software Statistica version 5.0
Statsoft Inc., Tulsa, Oklahoma).
esults
atients. Among patients consecutively referred for TAVI,
60 were at high risk or had contraindications to surgery.
he algorithm for treatment is shown in Figure 1. Of these
atients, 51 (32%) were treated with transfemoral TAVI
nd 24 (15%) were treated with transapical TAVI because of
ontraindications to the transfemoral approach. Twenty-
hree (14%) were reoriented toward conventional AVR,
ainly due to the presence of an aortic annulus, which is too
arge for TAVI (25 mm), associated with a surgical risk
rofile that was not considered prohibitive (EuroSCORE
0  11%, range 6% to 50%). Sixty-two patients (39%)
ere considered too frail, with a life expectancy too short to
ndergo any invasive intervention, or had technical contra-
ndications to both TAVI and AVR and were treated
edically (EuroSCORE 32  19%, range 3% to 86%).
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Characteristics
Overall
(n  75)
Age, yrs, mean  SD 82 8
Female sex 34 (45)
NYHA functional class
II 4 (5)
III 40 (53)
IV 31 (41)
Coronary artery disease 45 (61)
Previous MI 15 (20)
Previous PCI 11 (22)
Previous CABG 23 (31)
Peripheral artery disease 11 (15)
Renal failure 28 (38)
Severe COPD 20 (27)
Cancer 20 (27)
Porcelain aorta 9 (12)
2 comorbidities 43 (58)
Aortic valve area, mean  SD
cm2 0.64 0.16
cm2/m2 0.37 0.09
Mean gradient, mm Hg  SD 52 15
LVEF, % 51 15
Logistic EuroSCORE, %
Mean  SD 26 13
Range 6–65
STS-PROM, %
Mean  SD 16 7
Range 3–41
CI to surgery* 34 (45)
Values are expressed as n (%) unless otherwise stated. *Mainly porce
CABG was not considered an absolute CI to surgery.
CABG  coronary artery bypass grafting; CI  contraindication; COP
for Cardiac Operative Risk Evaluation; LVEF  left ventricular ejection
PCI percutaneous coronary intervention; STS-PROM Society of Thoracic S
implantation.The population studied here consisted of the 75 patients
ho were treated with either transfemoral or transapical
AVI. Its characteristics are detailed in Table 1. Overall, the
opulation was at high surgical risk, and the risk profile
ended to be even more severe in the transapical than in
he transfemoral subset. Seven patients (9%) had both
uroSCORE 20% and an STS-PROM 10%. For
hem, indications for TAVI were represented by absolute
ontraindications to conventional AVR due to severe
espiratory failure (n  3), chest radiation sequelae (n 
), a voluminous intracerebral aneurysm (n  1), or
orbid obesity (n  1).
n-hospital outcomes. In-hospital outcomes are detailed
n Table 2. Implantation success was achieved in 70 patients
93%). In all cases, aortic valve area and mean transpros-
hetic gradient were satisfactory. Technical failures occurred
nly in the transfemoral approach. Reasons for failure
ncluded the inability to pass the iliac artery in 3 patients, to
ross the aortic valve with the prosthesis in 1 patient, and
emopericardium in 1 patient due to perforation of the left
pulation
sfemoral TAVI
(n  51)
Transapical TAVI
(n  24) p Value
82 7 82 10 0.75
26 (51) 8 (33) 0.15
0.70
2 (4) 2 (8)
27 (53) 13 (54)
22 (43) 9 (38)
25 (49) 20 (87) 0.001
4 (8) 11 (48) 0.001
7 (20) 4 (27) 0.60
11 (22) 12 (52) 0.01
4 (8) 7 (30) 0.02
16 (31) 12 (52) 0.09
14 (27) 6 (26) 0.9
14 (27) 6 (26) 0.9
3 (6) 6 (26) 0.01
26 (51) 17 (74) 0.06
.63 0.16 0.65 0.17 0.72
.36 0.10 0.37 0.09 0.94
54 15 48 14 0.07
52 16 48 13 0.24
25 13 28 13 0.43
6–65 11–57
15 7 18 9 0.09
3–26 7–41
19 (37) 15 (63) 0.04
ta, sequelae of chest radiation, or severe respiratory failure. Previous
ronic obstructive pulmonary disease; EuroSCORE  European System
n; MI  myocardial infarction; NYHA  New York Heart Association;ndy Po
Tran
0
0
lain aor
D  ch
fractiourgeons Predicted Risk of Mortality; TAVI transcatheter aortic valve
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Transcatheter Aortic Valve Implantation July 21, 2009:303–11entricle, leading to intraprocedural death. There was nei-
her prosthesis embolization nor conversion to on-pump
urgical AVR. Immediately after implantation, paravalvular
eaks were observed in more than one-half of the patients.
hey were grade II or greater in 13 patients (17%), but were
rade III or greater in only 4 patients (5%). The incidence
f aortic regurgitation grade II or greater was related to a
arger annulus diameter (p  0.001) and greater patient
eight (p  0.01). Five patients underwent redilation for
aravalvular leaks. In 1 patient, redilation did not improve
he degree of regurgitation. In another, redilation induced a
assive intravalvular regurgitation, and emergent implanta-
ion of a second prosthesis into the first one (“valve after
alve”) was necessary, with good results. At the end of the
rocedure, 2 patients had grade III paravalvular aortic
egurgitation, with no hemodynamic consequences (no
hange in the clinical condition or pattern of the aortic
ressure and no increase in left ventricular filling pressures).
wo other patients had a second valve implanted into the
rst one in a higher position because the placement of the
rst one was deemed too low.
Three strokes (6%) occurred after transfemoral TAVI.
hey were diagnosed immediately after the procedure in 2
atients and 5 days later in a third, with full recovery within
months in all cases. No causative factor was found. There
ere no strokes in the transapical group. Four atrioventric-
lar blocks requiring pacemaker implantation occurred
n-Hospital Outcomes in the Study PopulationTable 2 In-Hospital Outcomes in the Study Population
Outcomes
Ove
(n 
Implantation success 70 (
Aortic valve area
cm2 1.73
cm2/m2 1.01
Mean gradient, mm Hg
Mean  SD 10
Range 3–2
Paravalvular aortic regurgitation
Grade 0 5 (
Grade I 52 (
Grade II 9 (
Grade III 4 (
“Valve after valve” 3 (
Major vascular complications 8 (
Stroke 3 (
Tamponade 4 (
Heart block* 4 (
In-hospital death 8 (
Per procedure 2 (
Cardiac 7 (
Noncardiac 1 (
Length of stay in ICU (days), median [25th–75th percentiles] 3 [2
Length of hospital stay (days), median [25th–75th percentiles]† 12.5 [9
alues are expressed as n (%) or mean  SD unless otherwise stated. *Requiring pacemaker imp
ICU  intensive care unit; TAVI  transcatheter aortic valve implantation.5%): 2 per procedure, 1 at day 4, and 1 2 weeks after the lrocedure. No coronary event leading to clinical, angio-
raphic, or electrocardiographic consequences was ob-
erved. However, troponin levels were not systematically
ecorded.
The most frequent major complications were vascular in
patients (11%). There were 4 iliac dissections in the
ransfemoral group: 3 were treated by surgical grafting, with
neventful outcomes in 2 patients, and post-operative death
t day 4 in 1 patient; 1 was treated by iliac stenting,
omplicated by acute leg ischemia due to stent occlusion on
ay 1, requiring emergency surgery, with a favorable out-
ome. There was 1 femoral injury at the entry site requiring
urgical grafting, and 1 hematoma in the contralateral groin
equiring a surgical evacuation. Two vascular complications
ccurred in the transapical group: 1 was secondary to the
elayed rupture of the femoral arterial access site (1 week
fter TAVI), and 1 to thrombosis of the common iliac artery
n the context of septic shock in a patient with severe
eripheral artery disease, leading to death.
Four tamponades occurred: 2 during transfemoral proce-
ures (1 perforation of the left ventricular apex, previously
entioned, and 1 rupture of the aortic annulus), leading to
ntraprocedural deaths; 1 4 h after a transapical procedure,
ith satisfactory recovery after surgical drainage, and 1 2
ays after a transapical procedure, due to rupture of the left
entricular apex, requiring emergent reintervention and
Transfemoral TAVI
(n  51)
Transapical TAVI
(n  24) p Value
46 (90) 24 (100) 0.05
1.70 0.37 1.80 0.48 0.46
0.97 0.20 1.08 0.27 0.13
11 4 9 4 0.11
6–21 3–20
0.36
3 (6) 2 (8)
33 (72) 19 (80)
8 (18) 1 (4)
2 (4) 2 (8)
1 (2) 2 (8) 0.20
6 (12) 2 (8) 0.65
3 (6) 0 0.23
2 (4) 2 (8) 0.15
3 (6) 1 (4) 0.75
4 (8) 4 (16) 0.22
2 (4) 0
4 (8) 3 (12)
0 1 (4)
2.5 [2–4] 5 [3–8] 0.001
13 [9–16] 12 [9–18] 0.89
on. †From procedure to discharge.rall
75)
93)
0.41
0.21
4
1
7)
75)
13)
5)
4)
11)
4)
5)
5)
10)
3)
9)
1)
–5]
–16]eading to multiorgan failure and death at day 39. Causes of
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July 21, 2009:303–11 Transcatheter Aortic Valve Implantationeaths are detailed in Table 3. All-cause in-hospital mor-
ality was 10%.
A comparison of hospital outcomes between the first 25
nd last 50 patients is shown in Table 4. According to
redictive mortality risk scores, the risk profile tended to be
orse in the first than in the last patients. It showed a higher
mplantation success rate and a significant decrease in the
requency of severe paravalvular regurgitation and hospital
ortality in the last compared with the first patients. In the
atients redirected to AVR, in-hospital mortality was 14%.
idterm outcomes. Mean follow-up duration was 10  6
onths (range 1 to 27 months). Six deaths occurred after
ischarge. Their causes are detailed in Table 3. One-year
urvival rates were 78 6% for the whole TAVI cohort, 81
% and 74  9% for the transfemoral and transapical subsets,
espectively (Fig. 2). Survival rates of the first 25 patients are
Causes of Death in 75 Patients Treated With TATable 3 Causes of Death in 75 Patients Tre
Time Approach Days to Death
In-hospital TF 0
In-hospital TF 0
In-hospital TF 1
In-hospital TA 2
In-hospital TF 4
In-hospital TA 18
In-hospital TA 39
In-hospital TA 61
Post-discharge TA 31
Post-discharge TA 77
Post-discharge TF 79
Post-discharge TF 165
Post-discharge TF 347
Post-discharge TF 445
*As initially determined by transesophageal echocardiography, and th
AR aortic regurgitation; DRESS drug rash with eosinophilia and s
other abbreviations as in Table 1.
omparison of Risk Profiles and Hospital Outcomesn First 25 and Last 50 Patients Treated Withranscatheter Aortic Valv Implantation
Table 4
Comparison of Risk Profil s and H spital Outcomes
in First 25 and Last 50 Patients Treated With
Transcatheter Aortic Valve Implantation
Variable First 25 Patients Last 50 Patients p Value
EuroSCORE, % 31 14 23 11 0.02
STS-PROM, % 17 7 15 7 0.17
CI to surgery 13 (52) 21 (42) 0.41
Implantation success 21 (84) 49 (98) 0.02
Paravalvular regurgitation 0.04
Grade 0 1 (5) 4 (8)
Grade I 13 (62) 39 (80)
Grade II 4 (19) 5 (10)
Grade III 3 (14) 1 (2)
Major vascular complications 4 (16) 4 (8) 0.29
Stroke 0 3(6) 0.21
Tamponade 2 (8) 2 (4) 0.76
Heart block* 0 4 (8) 0.1
In-hospital death 6 (24) 2 (4) 0.01
alues are expressed as n (%) or mean  SD unless otherwise stated. *Requiring pacemaker
mplantation.
Abbreviations as in Table 1.ompared with those of the last 50 patients in Figure 3. At 1
ear, the survival rate was 60  10% among the first patients
ompared with 93  4% among the last patients (p  0.001).
ith models using the EuroSCORE and the STS-PROM,
ultivariate analysis showed that early experience was the only
ignificant predictor of late mortality (hazard ratio: 8.9, 95%
onfidence interval: 2.3 to 34.6; p  0.002, and hazard ratio:
.2, 95% confidence interval: 1.9 to 27.1; p  0.004, respec-
ively) (Table 5).
A pericardial effusion occurred 1 month after a transapical
AVI and was treated with surgical drainage. A false
neurysm of the apex of the left ventricle occurred 2 months
fter a transapical TAVI and was treated by surgical closure,
ith an uneventful recovery. There was no other reinter-
ention, hemolysis, or permanent valve-related impairment.
Figure 2 Survival After TAVI
Kaplan-Meier survival in the 75 patients treated with transcatheter aortic valve
implantation, and in those treated with transfemoral or transapical approaches.
AVI  aortic valve implantation; other abbreviations as in Figure 1.
With TAVI
Cause of Death
Hemopericardium (LV perforation); intraprocedural death
Hemopericardium (annular rupture); intraprocedural death
Sudden, unexplained death
Intractable arrhythmias, heart failure
Iliac dissection; multi-organ failure after vascular surgery
Septic shock, leg ischemia
LV rupture at day 2, multiorgan failure after reintervention
DRESS syndrome
Pulmonary infection
Progressive physiological deterioration
Chronic renal failure, sudden unexplained death
Pulmonary infection
Heart failure (grade II paraprosthetic AR*)
Heart failure (grade III paraprosthetic AR*)
luated by transthoracic echocardiography during follow-up.
syndrome; LV left ventricular; TA transapical; TF transfemoral;VIated
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Transcatheter Aortic Valve Implantation July 21, 2009:303–11t the last follow-up of the 61 survivors, 20 (33%) were in
ew York Heart Association (NYHA) functional class I, 35
57%) were in class II, and 6 (10%) were in class III.
Follow-up of the echocardiographic parameters is shown
n Figures 4A and 4B. No structural valve deterioration or
ysfunction was observed. In the patients redirected to
VR, 1-year survival was 83  8%.
iscussion
his prospective study reports the management of patients
ith severe symptomatic AS and high risk for, or contra-
ndications to AVR, using all contemporary techniques of
AVI (i.e., either transfemoral or transapical approach
ollowing a uniform assessment). In this strategy, as com-
ared with the use of the transfemoral approach alone, a
igher number of patients were allowed to undergo inter-
ention. One-year survival and functional results were good.
utcome was closely related to experience.
umber of patients being treated. The European Heart
urvey showed that many high-risk patients with AS are not
ffered operations (1,2). The development of TAVI led to
n increase in the number or patients who can undergo
nterventions. Furthermore, the availability of both trans-
emoral and transapical approaches increased the number of
hose patients, in comparison with the use of the transfemo-
al approach alone. Although only one-third of the patients
tudied were candidates for transfemoral TAVI, use of the
ransapical approach extended the feasibility of TAVI to
7%. Moreover, reconsideration of conventional surgery in
ome others further increased the number of patients treated
ffectively, up to 61%. Most remaining patients who were
reated medically had severe comorbidities, severely limiting
heir life expectancy or precluding any functional benefit
rom TAVI.
Another study, conducted with the Edwards SAPIEN
Figure 3 Impact of Learning Curve on Survival
After Transcatheter Aortic Valve Implantation
Kaplan-Meier survival in the first 25 versus last 50
patients treated with transcatheter aortic valve implantation.alve, using either transfemoral or transapical approaches,
*oncluded that 75% of the patients evaluated for TAVI
ctually underwent the procedure (18). However, this study
ncluded only 29 patients.
Our results are closer to those previously reported using
he CoreValve Revalving System (CRS, CoreValve Inc.,
rvine, California), which showed that among high-risk
atients referred for TAVI, 28% were not eligible and 14%
ere redirected toward surgical AVR (23). But because of
he absence of alternative transapical approaches with this
atter device, the use of TAVI was restricted to 39% of the
atients; 3% underwent percutaneous aortic balloon valvu-
oplasty only, and another 16% refused treatment.
In the future, the number of candidates for TAVI will be
losely conditioned by the ability to decrease the sheath size
or the transfemoral approach and increase the valve size for
ll approaches, which are currently the main technical
imitations of the technique.
n-hospital mortality. Recent studies have shown that
VR can be performed in properly selected elderly patients,
ith operative mortality rates around 10% (24–27). How-
ver, this figure cannot be extrapolated to the population of
he present study, characterized by a high surgical risk or
resenting contraindications to AVR. High risk was shown
y the predicted mortality rate, which was, on average, 26%
or the EuroSCORE and 16% for the STS PROM. The
0% hospital mortality observed in this series compares
avorably with these predicted mortality rates. But it is
cknowledged that predictive scores have limitations, par-
icularly the Logistic EuroSCORE, which tends to overes-
imate risk in the most severe patients (28,29).
The present mortality rate compares favorably with the 23%
0-day mortality observed in the first French feasibility studies,
hich addressed patients recruited on a compassionate basis
5). It is consistent with the 12% mortality rate reported by
ebb et al. (7) in 50 patients whose risk profile was similar to
hat observed in the present series (EuroSCORE 28%) and
ho were treated by transfemoral TAVI using the Edwards
APIEN prosthesis. Piazza et al. (10) reported an 8%
0-day mortality rate in 600 patients who were treated with
ransfemoral TAVI using the CoreValve Revalving System
nd included in a multicenter registry. However, their
ultivariate Analysis of the Predictorsf Late Mortality in Patients Treated With TAVITable 5 Multivari e Analysis of the Predictorsof Late Mortality in Patients Treated With TAVI
Model
Hazard
Ratio
95% Confidence
Interval p Value
Model using the EuroSCORE
Early* versus late† experience 8.9 2.3–34.6 0.002
Transapical versus transfemoral 2.7 0.9–8.1 0.08
Logistic EuroSCORE (1-point increase) 0.98 0.93–1.02 0.28
Model using the STS-PROM
Early* versus late† experience 7.2 1.9–27.1 0.004
Transapical versus transfemoral 2.5 0.8–7.7 0.12
STS-PROM score (1-point increase) 0.99 0.93–1.06 0.86First 25 patients. †Last 50 patients.
Abbreviations as in Table 1.
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July 21, 2009:303–11 Transcatheter Aortic Valve Implantationverall risk profile tended to be lower than in the previous
tudies (EuroSCORE 23%). In comparison, hospital mor-
ality rates reported in transapical TAVI series tended to be
igher: 14% in the multicenter experience reported by
alther et al. (12), and 22.5% in the feasibility study
eported by Svensson et al. (14).
In the present series, hospital mortality was predominantly
ue to cardiovascular causes. This was also the case in the series
eported by Cribier et al. (5) and Webb et al. (7). As observed
n those previous reports, there was no valve-related death.
orbidity. Nonfatal morbidity could be considered ac-
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Figure 4 Echocardiographic Follow-Up After Transcatheter Aort
(A) Aortic valve area and mean transvalvular gradient follow-up after transcatheter
ventricular (LV) ejection fraction and systolic pulmonary artery pressure follow-up aeptable due to the high-risk nature of the population. mtrokes were rare (4%). All stroke patients recovered with-
ut sequelae. Consistent with previous reports, no stroke
ccurred after transapical TAVI (12). The incidence of
omplete atrioventricular blocks requiring pacemaker im-
lantation was low (5%), consistent with previous publica-
ions on the Edwards SAPIEN prosthesis (4–7,15) and
ower than rates reported with the CoreValve Revalving
ystem (9,10). There was no myocardial infarction, coronary
bstruction, or induced mitral valve dysfunction. Contrary to
ost previous TAVI series, there was no embolization. Ade-
uate pre-procedure annulus sizing and continuous TEE
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Transcatheter Aortic Valve Implantation July 21, 2009:303–11hus, the main cause of severe morbidity with the transfemoral
pproach remained vascular complications due to the large
iameters of the sheaths. This rate has already been decreased
y the reduction of the diameters with the CoreValve Revalv-
ng System (9).
-year results. Post-discharge mortality was due to non-
ardiac causes in one-half of the patients. These findings are
onsistent with those previously reported by Cribier et al.
5). Overall, late survival was consistent with that from
revious reports on transfemoral or transapical TAVI, when
sed separately.
The 81% 1-year survival rate obtained in the present
eries with the transfemoral approach compares favorably to
hose previously reported, ranging from 45% to 80% (5,7,9).
n patients who could not be treated by the transfemoral
oute and who underwent the transapical procedure, 1-year
urvival tended to be lower, but the difference did not reach
tatistical significance. The 74% 1-year survival rate ob-
erved here after transapical TAVI also compares favorably
ith the 72% survival at 3 months and the 60% survival at
months observed in a recent feasibility study (14). This
ate is more consistent with the 76% survival rate reported at
10-day follow-up in a multicenter study (12).
Functional results were good, with 90% of patients in
YHA functional class I or II at last follow-up; 94% were
n NYHA functional class III or IV before intervention.
his is of particular importance in the elderly, in whom the
im of intervention is essentially to improve the quality
ather than the duration of life.
redictive factors of outcome. As previously reported (7),
his study shows the presence of a learning period with a
irect impact on patients’ outcomes. In fact, the incremental
mprovements acquired during the TAVI program may
ave affected patient selection, as well as the implantation
echnique itself, and post-procedural management. The
hort- and mid-term outcomes were better in the last than
n the first patients and this difference remained highly
ignificant in multivariate analysis adjusting for risk profile
nd the type of procedure. The 2 fatal vascular complica-
ions were observed at the beginning of the experience. This
as also the case for the 2 grade II post-implantation
aravalvular leaks associated with midterm mortality. The
ecrease in the incidence of paravalvular leaks in the later
xperience may have been related to better echocardio-
raphic evaluation of annulus diameters and positioning of
he prosthesis.
Multivariate analysis also suggested that the transapical
pproach, compared with the transfemoral approach, is
ssociated with a negative trend, albeit not significant, on
utcomes. The strategy used here is likely to restrict the
ransapical approach to the highest risk patients, in partic-
lar, those with peripheral artery disease. In the present
eries, patients who underwent the transapical approach had
ore frequent coronary artery disease, previous coronary
rtery surgery and myocardial infarction, renal failure, and
xtracardiac comorbidities. Thus, the higher risk profile ofhe current transapical group may, at least in part, explain
he difference in results. Although several complications of
AVI are common to both approaches, transapical TAVI
equires a thoracotomy, potentially leading to specific post-
perative complications.
The fact that the STS-PROM and the EuroSCORE
ere not predictive of in-hospital outcome may be due to
linical or morphologic variables unrecognized by these
cores, or to the influence of the learning curve.
tudy limitations. This study reflects a single-center expe-
ience on a relatively limited number of patients. Sample
ize is an issue with respect to multivariate analysis since the
umber of end points is too small to avoid over-fitting.
owever, the present study allowed a uniform assessment
nd selection strategy in the entire population, as well as
ata collection and analysis. It is also an initial experience.
s the learning curve had a crucial and direct influence on
linical outcomes, the true benefit/risk ratio of the technique
ay have been underestimated in the present report. This
tudy was not randomized, and no fair conclusion on the
omparative clinical benefits of transfemoral and transapical
pproaches can be drawn from its results.
onclusions and Future Directions
oday, TAVI allows patients who are at very high surgical
isk or with contraindications to surgical AVR to benefit
rom an effective treatment of AS, and the availability of
oth transfemoral and transapical approaches increases the
umber of patients who can be treated. One-year results are
atisfactory in terms of survival as well as functional im-
rovement, in particular, given the patients’ risk profile. The
lose impact of the learning curve on patients’ outcomes
nderlines the necessity of proper training, and the restric-
ion of these procedures to high-volume centers (17). In the
uture, randomized controlled trials and comprehensive regis-
ries with longer follow-up will help to better define the safety
nd durability, and subsequently, indications of the technique,
nd the respective places of transfemoral and transapical
pproaches.
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